Ignite Creation Date:
2025-12-24 @ 10:22 PM
Ignite Modification Date:
2025-12-30 @ 6:55 PM
Study NCT ID:
NCT07069335
Status:
RECRUITING
Last Update Posted:
2025-07-16
First Post:
2025-07-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
Sponsor:
Boryung Pharmaceutical Co., Ltd
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-06-17
Start Date Type:
ACTUAL
Primary Completion Date:
2026-05-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-05-15
Completion Date Type:
ESTIMATED
First Submit Date:
2025-07-07
First Submit QC Date:
None
Study First Post Date:
2025-07-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-07
Last Update Post Date:
2025-07-16
Last Update Post Date Type:
ACTUAL